Search Results for "guaifenesin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for guaifenesin. Results 1 to 6 of 6 total matches.
See also: Mucinex, Sudafed

Over-the-counter (OTC) Cough Remedies

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
mg Guaifenesin 400 mg Contac Severe Cold and Flu Maximum Strength Caplets (GlaxoSmithKline ...
The number of cough remedies available in the USA continues to multiply, but most products contain the same or similar ingredients in varying combinations. Most acute coughs do not require treatment with drugs, especially in children, and suppression of a productive cough may be harmful.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):23-5 |  Show IntroductionHide Introduction

In Brief: Mucinex

   
The Medical Letter on Drugs and Therapeutics • Feb 14, 2005  (Issue 1202)
guaifenesin in a new FDAapproved OTC extended-release formulation. In recommended dosages, it is generally ...
Patients may be asking health care providers about the safety and effectiveness of Mucinex (Adams), which is being heavily advertised on television and elsewhere for treatment of respiratory congestion. These ads suggest that Mucinex is a new drug, when actually it is an extended-release formulation of guaifenesin, an old expectorant. Guaifenesin increases the volume of secretions in the respiratory tract, which facilitates removal of viscous mucus by coughing. Medical Letter consultants have not been impressed by its effectiveness. Guaifenesin is in the category of drugs - Generally...
Med Lett Drugs Ther. 2005 Feb 14;47(1202):16 |  Show IntroductionHide Introduction

Drugs for Cough

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 2018  (Issue 1562)
-filled capsule, is dangerous and should not be used. ▶ The expectorant guaifenesin can facilitate ...
Acute cough (<3 weeks in duration) generally does not require pharmacologic treatment, especially in children. Suppression of productive cough may be harmful. Management of patients with cough should include elimination of any precipitating factor (e.g., cigarette smoking) and treatment of any underlying cause such as upper airway cough syndrome, gastroesophageal reflux disease, asthma, or other pulmonary disease.
Med Lett Drugs Ther. 2018 Dec 17;60(1562):206-8 |  Show IntroductionHide Introduction

Hydrocodone/Chlorpheniramine (Vituz)

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2013  (Issue 1430)
ingestion by young children.3,4 Expectorants – Guaifenesin increases the volume of secretions ...
An oral solution (Vituz – Hawthorne) containing two old drugs, the centrally-acting opioid hydrocodone bitartrate and the first-generation H1-antihistamine chlorpheniramine maleate, has been approved by the FDA for relief of cough and [other] symptoms associated with upper respiratory allergies or a common cold in adults. Several extended-release products containing hydrocodone and chlorpheniramine are available as capsules and suspensions and have been used for years for similar indications. Vituz is classified as a schedule III controlled substance, but the FDA has asked the DEA...
Med Lett Drugs Ther. 2013 Nov 25;55(1430):95-6 |  Show IntroductionHide Introduction

Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
in fixed-dose combinations with acetaminophen, ibuprofen, homatropine, or guaifenesin $449.30 328.00 ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e199-202 |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
, homatropine, or guaifenesin 449.30 328.00 241.10 Benzhydrocodone/ acetaminophen – Apadaz (KVK Tech ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction